Synthetic DNA Vaccine
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "DNA and mRNA Vaccines".
Deadline for manuscript submissions: closed (25 April 2021) | Viewed by 396
Special Issue Editors
Interests: vaccine; infectious diseases; macrophage and T cell Biology; incRNA; incRNA-RBP (RNA Binding protein) interaction; epigenetics; chromatin architecture; gene regulation
Interests: vaccine; infectious diseases; macrophage biology
Special Issue Information
Dear Colleagues,
Live attenuated and inactivated pathogens are used as conventional vaccines have the poor assurance of safety as they may return to pathogenic form. On the other hand, subunit DNA vaccines avoid the risk of reversion. Analysis of DNA vaccines show the minimal level of side effects, not integrating into the host chromosome, and does not have anti-vehicle autoimmunity after vaccination. Thus, making it possible to administer multiple doses. The main advantage of DNA vaccines is their ability to stimulate both the humoral and cellular arms of the adaptive immune system.
The aim of this Special Issue is to collate original research that seeks to show the efficacy of DNA vaccines against pathogenic bacteria/virus/and parasitic infection.
Dr. Imran Chowdhury
Dr. Subhadip Choudhuri
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- DNA vaccine
- adjuvants
- T-cell
- B-cell
- NK cell
